Compare VNRX & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VNRX | IPSC |
|---|---|---|
| Founded | N/A | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.8M | 47.6M |
| IPO Year | N/A | 2021 |
| Metric | VNRX | IPSC |
|---|---|---|
| Price | $0.30 | $0.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $3.17 | $3.00 |
| AVG Volume (30 Days) | ★ 2.5M | 1.1M |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,472,007.00 | ★ $113,337,000.00 |
| Revenue This Year | $324.32 | $1,589.94 |
| Revenue Next Year | $247.82 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 14.48 | ★ 4122.69 |
| 52 Week Low | $0.29 | $0.34 |
| 52 Week High | $0.94 | $1.83 |
| Indicator | VNRX | IPSC |
|---|---|---|
| Relative Strength Index (RSI) | 32.33 | 47.22 |
| Support Level | $0.29 | $0.46 |
| Resistance Level | $0.33 | $0.56 |
| Average True Range (ATR) | 0.03 | 0.04 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 7.66 | 61.00 |
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.